Saffold virus (SAFV) was isolated from a stool sample of a child who presented with fever of unknown origin in 1981. In 2007, the virus was sequenced and identified as a Cardiovirus of the species Theilovirus, presenting the highest nucleotide identity with rat Theilovirus (RTV), a Theilovirus isolated from rats (Jones et al., 2007) . SAFV is the first Theilovirus that was clearly identified as a human virus. Other Theilovirus members are neurotropic viruses: Theiler's murine encephalomyelitis virus (TMEV), isolated from mouse; RTV; and Vilyuisk human encephalomyelitis virus, whose possible human origin is unclear (Lipton, 2008) . A subset of TMEV strains (persistent strains) have the intriguing ability to establish a persistent infection in the white matter of the central nervous system (CNS) despite a robust immune response of the host (Brahic et al., 2005) . When the virus persists in the CNS, it is responsible for an inflammatory demyelinating pathology that is reminiscent of human multiple sclerosis (MS) (Oleszak et al., 2004) . A recent study attempted to detect SAFV genomes in active brain lesions of MS patients, but results were negative (Galama et al., 2014) . Also, no reactivity to SAFV was detected in oligoclonal bands of MS patients' cerebrospinal fluid (CSF). In vitro, SAFV was reported to be able to persistentlyinfect HeLa cell cultures (Himeda et al., 2013) . A serological survey revealed that SAFV-3 and SAFV-2 (Chiu et al., 2010; Galama et al., 2011) seroprevalence can reach more than 90 % in the adult population, and that the infection occurs early in life (mainly before the age of two) (Zoll et al., 2009) . SAFV strains are circulating worldwide as seroprevalence was very high in America (Chiu et al., 2010) , Europe, Africa and Asia (Zoll et al., 2009) . Up to now, 11 different genotypes have been identified, with SAFV-1, SAFV-2 and SAFV-3 being the most prevalent (Drexler et al., 2008; Khamrin et al., 2013; Nielsen et al., 2012b; Tapia et al., 2015) . The virus was detected in the stools and respiratory samples of both symptomatic (gastrointestinal and respiratory symptoms) and asymptomatic patients. It was also detected in the stools of some patients presenting with acute flaccid paralysis (Naeem et al., 2014) , and in the CSF and myocardium of a child who died suddenly with no history of illness (Nielsen et al., 2012a) . However, no causative association between SAFV infection and any human pathology has been firmly established.
In order to get new insights into the pathogenesis potential of SAFV, we performed experimental mouse infection with virus strains belonging to the genotypes 2 and 3 that were isolated previously (Zoll et al., 2009) . Handling of mice (agreement LA1230472) and experimental procedures were †These authors contributed equally to this work. conducted in accordance with the EEC (European Economic Community) directive 86/609/CEE and the related Belgian law of 6 April 2010. The study and protocol used in this study were approved by the ethics committee of the University of Louvain under the agreement no. 2010/UCL/ MD/031. Three-week-old 129/Sv female mice were inoculated by the intraperitoneal (IP) route with 10 5 TCID 50 of SAFV-2 (n=4) or SAFV-3 (n=4) or were mock-infected (n=2). IP inoculation was chosen because it provides the virus access to peripheral tissues, while allowing testing of the neuroinvasive properties of the virus. Mice failed to develop clinical symptoms. Seven days post-infection (p.i.), viral load was quantified in different organs by reverse-transcription and quantitative PCR (RT-qPCR), using the SYBR Green method (Fig. 1a) . Primers used to detect SAFV were 5¢-TGTAGCGACCTCACAGTAGCA-3¢ (sense) and 5¢-CAGGACATTCTTGGCTTCTCTA-3¢ (antisense). Primers used to detect mRNA encoding b-actin were described previously (Sommereyns et al., 2008) .
SAFV-2 and SAFV-3 exhibited a similar tropism. Viral genome was detected in the heart, pancreas, spleen, brain and spinal cord, but not in the intestine and thymus (Fig.  1a and data not shown). This pattern fits with the typical tropism of other Cardioviruses. Infection of the pancreas was striking and warrants further studies on the potential infection of this organ by SAFV in humans. The virus also showed some neuroinvasive potential, since both SAFV-2 and SAFV-3 viruses were detected in the brain and spinal cord after IP inoculation. Of note, SAFV-3 appeared to be slightly more neurotropic than SAFV-2 as viral load was slightly higher for SAFV-3 than for SAFV-2 in CNS and slightly lower in the other tissues. In vitro, in primary hippocampal neuron cultures prepared by the protocol of Fath et al. (2009) , SAFV-3 also replicated more efficiently than SAFV-2 (Fig. 1b) .
Some TMEV strains have a striking ability to persist in the CNS of susceptible mice (Brahic et al., 2005) . Susceptibility notably depends on the haplotype of the mice as H-2 b mice were shown to clear TMEV infection by mounting a strong cytotoxic T lymphocyte response against an immunodominant epitope present in the VP2 capsid protein and conserved among TMEV and SAFV strains (Dethlefs et al., 1997) . To assess the ability of SAFV to persist in the CNS, FVB/N mice (H-2 q haplotype) were inoculated intracerebrally with 10 5 TCID 50 SAFV-2 (n=5) or SAFV-3 (n=5), and viral load was measured by RT-qPCR in brain and spinal cord, 6 weeks after inoculation. This mouse strain was previously shown to be susceptible to SAFV-2-mediated early encephalitis after intracranial inoculation (Hertzler et al., 2011) . At 45 days p.i., SAFV-2 was almost undetectable (1.8 ± 0.3Â10 1 SAFV per 10 6 b-actin cDNA copies) and SAFV-3 was present at a very low titre (2.4 ± 1.9Â10 2 SAFV per 10 6 b-actin cDNA copies) in the brain. Neither SAFV-2 nor SAFV-3 was detected in the spinal cord (< 10 1 SAFV per 10 6 b actin cDNA copies). Also, upregulation of the IFN-stimulated Oasl2 gene, measured by RT-qPCR (Sommereyns et al., 2008) , was weak (< three fold) in SAFV-inoculated mice, suggesting that very little viral replication was ongoing 45 days post-inoculation. Thus, SAFV-2 and SAFV-3 have a much lower ability to persist in the mouse CNS than persistent TMEV strains.
We next characterized the tropism of SAFV-3 in the CNS. Therefore, infection of WT 129/Sv mice (n=6) was repeated with a new SAFV-3 virus stock. In addition, a few (n=3) IFN-receptor 1-deficient 129/Sv mice (IFNAR-KO) were inoculated to evaluate the impact of type I IFN on neuroinvasion by SAFV (Fig. 1c) .
As in the experiment described in Fig. 1(a) , infection in WT mice was asymptomatic. Viral load was most prominent in the pancreas. Heart and spleen were also infected, but CNS infection only occurred in two out of six mice. Nevertheless, these data confirmed the neuroinvasive ability of SAFV-3 in the mouse model. In the case of IFNAR-KO mice, one mouse exhibited severe signs of encephalitis (ruffled fur, hunched back, ataxia) and had an extremely high viral load in the CNS and in other organs analysed. One asymptomatic IFNAR-KO mouse had a lower, yet elevated, viral load in the CNS, and one had a low viral load in all organs. Thus, for two out of three IFNAR-KO mice, CNS infection was particularly high, suggesting that the type I IFN response critically acts to control neuroinvasion. Influence of type I IFN was less striking in other tissues (Fig. 1c) .
To define the cellular tropism of SAFV-3 in the CNS of IFNAR-KO mice, two antibodies were produced that allow SAFV detection by immunohistochemistry. A polyclonal chicken antibody was raised against the VP1 capsid protein of SAFV-3. For this purpose, SAFV-3 VP1 was purified from Escherichia coli as a His-tag fusion and used to immunize chickens. Polyclonal antisera were collected and tested for specificity on infected cell cultures. IgY was then purified from egg yolk as described elsewhere (Jensenius et al., 1981) . This antibody was used for immunohistochemistry (paraffin sections) at a dilution of 1/500. We also used a rabbit polyclonal antiserum directed against peptide CADYYKQR-LIHDVEMNPG, which corresponds to the C-terminal 17 aa of TMEV (DA) 2A protein preceded by a cysteine residue that allowed conjugation to maleimide activated keyhole limpet haemocyanin (Pierce) before rabbit immunization (CER). The antiserum directed against TMEV 2A partly cross-reacted with SAFV 2A and allowed the detection of SAFV-infected cells in paraffin sections (Fig. 2g) .
among SAFV-3 infected IFNAR-KO mice, viral load correlated among different organs (i.e. the mouse that had the highest viral load in the brain also had the highest viral load in other organs). Statistics: Mann-Whitney two-tailed test ( * P< 0.05; ** P< 0.01; *** P<0.001; NS, non-significant).
VP1-no primary 2A 2A-no primary For immunostaining, WT and IFNAR-KO 129/Sv mice were IP infected with 10 5 TCID 50 SAFV-3. After sacrifice, brains and spinal cords were collected and embedded in paraffin. Sections were immunolabelled with anti-VP1 or anti-2A antibodies, and with antibodies directed against cell-specific markers: astrocytes (GFAP; Dako), neuron (MAP2; Synaptic Systems; or NeuN; Millipore). WT mice developed no symptoms and viral antigen was not detected in analysed sections (not shown). In contrast, 6 days after IP infection, all IFNAR-KO mice (n=4) developed severe encephalitis symptoms (ruffled fur, hunched posture, paralysis) comparable to those of the heavily infected mouse analysed above (Fig. 1c ). Mice were thus sacrificed and tissues were processed for immunostaining. The virus was found in many parts of the brain and of the spinal cord. Viral antigen was detected in both neurons and astrocytes. Infected neurons were mostly detected in the cortex and the hippocampus (Fig. 2b, c, f) . Astrocyte infection was, however, more pronounced, notably in the cerebellum, brainstem and thalamus where large infection foci that resemble plaques were observed (Fig. 2a) . In the cerebellum, SAFV-3 caused extensive infection of the Bergmann glia (Fig. 2d, e) .
In vitro, SAFV-3 also exhibited a marked tropism for astrocytes in mixed mouse primary neuron-astrocyte cultures. At 8, 16 and 24 h p.i. with 4 TCID 50 SAFV-3 per cell, viral antigen accumulated much more in GFAP-positive (astrocytes) than in MAP2-positive (neurons) cells (Fig. 3a-c) . We reported previously that IFN-a/b treatment poorly protected primary mouse neurons against infection by the GDVII strain , before infection for 12 h with SAFV-3. Graphs show the mean and SD of the percentage of infected neurons and astrocytes in an experiment involving three parallel culture infections. The biological influence of IFN-b treatment was confirmed in an independent experiment involving four parallel infections. *, P 0.05 by one-tailed Mann-Whitney test.
of TMEV (Kreit et al., 2014) . To test the protective effect of IFN against SAFV-3 in neurons and astrocytes, mixed cultures were treated for 24 h with 10 IU murine IFN-b ml À1 produced as described by Kreit et al. (2014) or with control medium, and then infected by SAFV-3 at an m.o.i. of 4. Twelve hours after infection, cells were fixed and immunolabelled as in the former experiment, and the percentage of infected cells was counted (Fig. 3c) . Although visible, neuron protection was difficult to quantify, as the percentage of infected neurons was low. Astrocytes were strongly protected by IFN-b as the percentage of infected cells decreased by 12-fold after IFN-b treatment. Taken together, the in vivo and the in vitro data suggest that SAFV-3 has a pronounced tropism for astrocytes, but that these cells are strongly protected by the IFN response.
In conclusion, this work reports a preliminary characterization of SAFV tropism in the mouse model. Both SAFV-2 and SAFV-3 strains exhibit a pronounced tropism for the pancreas, which warrants further studies about the possible involvement of SAFV in pancreatic diseases in humans. In addition SAFV can infect the heart and the CNS, as expected for a member of the genus Cardiovirus. These observations are congruent with those of Kotani et al. (2016) , which were published while this paper was in revision. These authors report the neuropathogenicity in mice, of two SAFV-3 clinical isolates. Our data further show that SAFV-3 exhibits a pronounced cellular tropism for astrocytes. These cells, however, appear to be potently protected from SAFV infection by the type I IFN response.
